Ionis Pharmaceuticals
Antisense oligonucleotide platform and therapeutics
New patent ·
- Sector
- Biotech
- Total capital
- $8.4M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $8.4M
- 6 awards · Defense, Health and Human S
- Rank in Biotech#63 of 4373
- Granted patents
- 16
- 24 pending · first 2025
- Rank in peer group#4 of 1449
Capital timeline
Latest events
- Federal contractHealth and Human S · T-5000 Biosensor$500K
- Federal contractHealth and Human S · 000HCK75-2006-36858 - SBIR Phase I Contract$100K
- Federal contractDefense · Phase I Monthly Reports (5)$778K
- Federal contractDefense$706K
- Federal contractHealth and Human S · Assessing The Safety Of Cell Substrates And Vaccine Components$5.6M
- Federal contractDefense$680K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#4 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 16 granted of 40- New patentOligomeric Compounds Comprising Bicyclic Nucleotides and Uses ThereofUSPTOUS 12,767,948
- New patentSynthesis Of Oligomeric Compounds Comprising Phosphorothioate Diester And Phosphodiester LinkagesUSPTOUS 12,747,260
- GrantedCompounds And Methods For Reducing Pln ExpressionUSPTOUS 12,742,170
Show all 40 patent records
- Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses ThereofOct 20, 2026 · US 12,767,948Granted
- Synthesis Of Oligomeric Compounds Comprising Phosphorothioate Diester And Phosphodiester LinkagesSep 29, 2026 · US 12,747,260Granted
- Compounds And Methods For Reducing Pln ExpressionSep 22, 2026 · US 12,742,170Granted
- Compounds And Methods For Reducing Fus ExpressionSep 15, 2026 · US 12,735,700Granted
- Compounds And Methods For Modulating Angiotensinogen ExpressionSep 10, 2026 · Application 19455543Pending
- Conjugated Antisense Compounds And Their UseSep 3, 2026 · Application 19461621Pending
- Conjugated Antisense Compounds And Their UseAug 27, 2026 · Application 19461618Pending
- Compositions And Methods For Modulating Ttr ExpressionAug 13, 2026 · Application 19408484Pending
- Compounds and Methods for Reducing KCNT1 ExpressionAug 13, 2026 · Application 19652847Pending
- Methods for Reducing HTT ExpressionAug 13, 2026 · Application 19659031Pending
- Methods for Deprotecting and Purifying Oligonucleotide CompoundsJul 2, 2026 · Application 19131179Pending
- Compounds and Methods for Reducing ATXN3 ExpressionJul 2, 2026 · Application 19566591Pending
- Compositions for Modulating Ataxin 2 ExpressionJul 2, 2026 · Application 19545773Pending
- Methods for Modulating Complement Factor B ExpressionJun 25, 2026 · Application 19126841Pending
- Compounds And Methods For Modulating Angiotensinogen ExpressionJun 23, 2026 · US 12,662,508Granted
- Modulation of Apolipoprotein C-III (ApoCIII) Expression in Lipoprotein Lipase Deficient (LPLD) PopulationsJun 18, 2026 · Application 19296688Pending
- Compositions and Methods for Treating and Preventing Prekallikrein-Associated ConditionsJun 11, 2026 · Application 19271374Pending
- Methods For Safely Reducing ThrombopoietinJun 4, 2026 · Application 19391725Pending
- Compositions for Modulating C9ORF72 ExpressionJun 4, 2026 · Application 19464245Pending
- Compositions And Methods For Enhanced Intestinal Absorption Of Conjugated Oligomeric CompoundsMay 28, 2026 · Application 19458402Pending
- Modulation of Apolipoprotein C-III (ApoCIII) Expression in Lipoprotein Lipase Deficient (LPLD) PopulationsMay 14, 2026 · Application 19447664Pending
- RNAi AGENTS FOR MODULATING SNCAMay 14, 2026 · Application 18863476Pending
- Compounds And Methods For Modulating PLP1May 12, 2026 · US 12,624,356Granted
- Compounds And Methods For Reducing Pln ExpressionMay 12, 2026 · US 12,624,358Granted
- Compounds And Methods For Reducing ATXN3 ExpressionMay 5, 2026 · US 12,618,069Granted
- Compounds and Methods for Reducing ATXN3 ExpressionApr 30, 2026 · Application 19229347Pending
- Modulation Of Transthyretin ExpressionApr 21, 2026 · US 12,606,826Granted
- Compositions And Methods For Modulating MECP2 ExpressionApr 16, 2026 · Application 19223874Pending
- Compositions for Modulating C9ORF72 ExpressionApr 14, 2026 · US 12,600,970Granted
- Linkage Modified Oligomeric Compounds And Uses ThereofApr 7, 2026 · US 12,595,482Granted
- Modulation Of Prekallikrein (pkk) ExpressionApr 7, 2026 · US 12,595,485Granted
- Compounds And Methods For Modulating SMN2Mar 26, 2026 · Application 19197566Pending
- Compositions For Modulating Ataxin 2 ExpressionMar 24, 2026 · US 12,584,128Granted
- Compositions And Methods For Modulating Apolipoprotein C-iii ExpressionFeb 5, 2026 · Application 19088598Pending
- RNAi AGENTS OF PRION EXPRESSIONJan 29, 2026 · Application 18841971Pending
- Compositions and Methods for Modulating Complement Factor B ExpressionJan 22, 2026 · Application 19256127Pending
- Methods And Compositions For Inhibiting PMP22 ExpressionJan 20, 2026 · US 12,529,055Granted
- Compositions And Methods For Modulating Ttr ExpressionJan 6, 2026 · US 12,516,319Granted
- Compounds And Methods For Reducing Prion ExpressionJan 1, 2026 · Application 19047251Pending
- Compositions And Methods For Modulating Apolipoprotein C-iii ExpressionDec 30, 2025 · US 12,509,684Granted
Related companies, and why
- SACHI BIOWORKS, INC.Similar federal contract value in Biotech · $9.8M in contracts
- INNOVATION PATHWAYS, LLCSimilar federal contract value in Biotech · $9.2M in contracts
- Noveome Biotherapeutics, Inc.Similar federal contract value in Biotech · $8.5M in contracts
- ARISAN THERAPEUTICS INCSimilar federal contract value in Biotech · $8.3M in contracts
- BNB PLUS CORP.Similar federal contract value in Biotech · $8M in contracts
- DISCOVERX CORPSimilar federal contract value in Biotech · $7.6M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .